BUND FINANCE

BUND FINANCE › Stocks › ARGX

argenx SE (ARGX)

NASDAQ · Stock price, chart and technical analysis

US$942.04+0.7900 (+0.08%)

Data from Financial Modeling Prep · Nov 19, 2026, 4:00 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$941.25
OpenUS$939.97
Day rangeUS$933.98 – US$950.06
52-week rangeUS$661.85 – US$1,072.75
Market capUS$59.24B
Volume284,209
50-day averageUS$919.83
200-day averageUS$861.84
Beta-0.02

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$1.1BUS$410.7MUS$1.2BUS$2.2BUS$4.2B
Net income−US$408.3M−US$709.6M−US$295.1MUS$833.0MUS$1.3B
EPS (diluted)-7.99-13.05-5.1612.7819.63
Gross margin46.1%92.8%90.4%89.6%89.2%
Operating margin-32.4%-175.4%-34.7%-1.0%25.4%
Net margin-37.9%-172.8%-24.1%38.0%31.1%
Free cash flow−US$728.2M−US$966.6M−US$464.1M−US$151.0MUS$679.0M
Total debtUS$11.5MUS$12.4MUS$20.0MUS$39.1MUS$83.5M
CashUS$1.3BUS$800.7MUS$2.0BUS$1.5BUS$3.5B

Compound annual growth: revenue 40.1% · net income — (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E23.3x42.0x26.4x
EV / EBITDA19.9x186.4x16.3x
Operating margin27.5%—3.6%
Net margin30.3%—-0.0%
Debt / equity0.19—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About argenx SE

SectorHealthcare
IndustryBiotechnology
CountryNL
CEOKaren Massey
Employees1,863
IPO date2017-05-18

argenx SE is a biotechnology enterprise dedicated to developing a diverse array of therapeutic agents for autoimmune conditions. Its operational reach extends across the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France. The company's primary drug candidate, efgartigimod, is currently in advanced stages of clinical investigation. It is being evaluated in Phase III trials for several indications, including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. Furthermore, efgartigimod is progressing through Phase II/III clinical trials for bullous pemphigoid and idiopathic inflammatory myopathy, wi…

www.argenx.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice